fludarabine has been researched along with Immunologic Deficiency Syndromes in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 7 (50.00) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B | 1 |
Barhoom, D; Behfar, M; Hamidieh, AA; Mohseni, R | 1 |
Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A | 1 |
Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Pourpak, Z; Yari, K | 1 |
Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C | 1 |
Behfar, M; Faghihi-Kashani, S; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Moin, M; Movahedi, M; Mozafari, M; Pourpak, Z | 1 |
Adams, S; Allwood, Z; Amrolia, P; Chiesa, R; Lucchini, G; Qasim, W; Rao, K; Silva, J; Veys, P; Worth, A | 1 |
Adams, S; Amrolia, PJ; Berrie, E; Bird, P; Brenner, MK; Brown, L; Davies, EG; Eyrich, M; Gaspar, HB; Gennery, AR; Goulden, N; Hale, G; Landais, P; Rao, K; Schlegel, PG; Straathof, KC; Veys, PA | 1 |
Burroughs, LM; Carpenter, PA; Englund, J; Ochs, HD; Rawlings, DJ; Sanders, J; Scharenberg, AM; Skoda-Smith, S; Storb, R; Torgerson, TR; Woolfrey, AE | 1 |
Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D | 1 |
Dalal, J; Davies, SM; Filipovich, A; Kamani, N; Lee, SM; Rao, A; Shenoy, S | 1 |
Aschan, J; Barkholt, L; Dahllöf, G; Gustafsson, B; Hassan, Z; Ljungman, P; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Svahn, BM; Svenberg, P; Uzunel, M; Winiarski, J | 1 |
Kipps, TJ | 1 |
Schilling, PJ | 1 |
1 review(s) available for fludarabine and Immunologic Deficiency Syndromes
Article | Year |
---|---|
Chronic lymphocytic leukemia.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine | 2000 |
5 trial(s) available for fludarabine and Immunologic Deficiency Syndromes
Article | Year |
---|---|
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2018 |
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2014 |
Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study
Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Child; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Male; Melphalan; Prospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine | 2016 |
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunologic Factors; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Leukocyte Common Antigens; Male; Rats; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Child, Preschool; Colitis; Endocrine System Diseases; Food Hypersensitivity; Forkhead Transcription Factors; Genes, X-Linked; Graft Survival; Humans; Ichthyosis, X-Linked; Immunologic Deficiency Syndromes; Infant; Leukocyte Count; Melphalan; Postoperative Complications; Reoperation; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
8 other study(ies) available for fludarabine and Immunologic Deficiency Syndromes
Article | Year |
---|---|
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Successful allogeneic stem cell transplantation with fludarabine-based reduced intensity conditioning in bone marrow failure syndrome 4.
Topics: Antineoplastic Agents; Bone Marrow Failure Disorders; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2021 |
Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2.
Topics: Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immune System; Immunologic Deficiency Syndromes; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Piebaldism; Primary Immunodeficiency Diseases; Prospective Studies; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2013 |
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen.
Topics: Cell Lineage; Chimerism; Disease-Free Survival; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Melphalan; Stem Cell Transplantation; Stem Cells; Vidarabine | 2016 |
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
Topics: Adolescent; Cell Separation; Child; Cyclosporine; Flow Cytometry; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Male; Mycophenolic Acid; Myeloablative Agonists; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunologic Deficiency Syndromes; Infant; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2007 |
Two views of the immunologic effects of fludarabine.
Topics: Antineoplastic Agents; Burkitt Lymphoma; CD4-Positive T-Lymphocytes; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Regulatory; Vidarabine | 1991 |